The purpose of this study is to see if vorinostat is safe for people with moderate-to-severe CD and to see if it is safe for people with moderate-to-sever CD to receive maintenance therapy using Ustekinumab after successful treatment of Vorinostat.

This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions.

The purpose of this study is to see if a drug called empagliflozin can help people with severe congenital neutropenia (SCN).

This purpose of this protocol is to evaluate selected patients with documented recurrent or unusual infections and their family members for clinical and laboratory correlates of immune abnormalities.

The purpose of this study is to provide a specimen bank of samples with carefully characterized clinical data.

SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.

The purpose of this study is to determine which regimen of pyrimethamine is most effective when combined with sulfadiazine and leucovorin in treating patients who have congenital toxoplasmosis.

The goal of this study is to identify genetic mutations responsible for CAEBV. A secondary goal is to learn more about the natural history of CAEBV.

This purpose of this study is to examine growth factors that promote and inhibit mast cell proliferation resulting in mastocytosis, a disease of excessive mast cells in the body.

This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment.